FairValu
JOHNSON & JOHNSON

JOHNSON & JOHNSON

JNJNYSE
Drug Manufacturers - General • Healthcarejnj.com
Current Price
$265.580.00%
Market Cap
$640.02B
Shares Outstanding: 2.41B
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

Strategic AI Analysis for JNJ

Checking whether the approved providers contain enough current financial data for a reliable report.

Summary

Source-linked company research for JNJ

Checking Factor Scorecard coverage

Financial statement coverage is being verified before factor scores are shown.

Price Chart

NYSE:JNJ via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available for this company.

No Data

No annual financial data available.

Financial Fundamentals

Growth, quality, valuation, cash generation, and balance-sheet strength.

Sector: Healthcare

Growth

TTM revenue plus current, long-term, forward, and accelerating top-line trends.

Revenue
-
Revenue Growth
8.1%
Moderate
Revenue CAGR 3Y
-
Forward Revenue Growth
7.4%
Moderate
Revenue Acceleration
-7.1%
Slowing

Earnings

Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.

EPS (TTM)
8.73
Profitable
EPS Growth
-7.2%
Declining
EPS CAGR 3Y
-
EPS Surprise
1.6%
Beat
Forward EPS
11.08
Profitable
Fwd Revenue Growth
7.4%
Forward EPS Growth
12.4%
Moderate

Profitability

TTM margin and return metrics that reflect pricing power and business quality.

Gross Margin
67.9%
High
Operating Margin
27.4%
High
Net Margin
21.5%
High
Margin vs Trend
-
ROE
24.8%
Excellent
ROIC
19.7%
Strong

Cash Flow

TTM free cash flow, growth, margin, and operating-cash conversion quality.

Free Cash Flow
$22.24B
Positive
FCF Growth
19.9%
Strong
FCF Margin
-
Cash Conversion
1.31x
Excellent

Valuation

Metrics ranked by issuer type, financial state, and input quality.

Established companyPrimary lens

Forward P/E

Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.

Forward P/EPrimary
23.98x
Typical
EV / EBITDASupporting
19.35x
Typical
EV / FCFSupporting
30.06x
High
Trailing P/ESupporting
30.42x
High

Financial Health

Latest-quarter liquidity and leverage checks plus TTM interest coverage.

Current Ratio
1.09x
Adequate
Quick Ratio
0.73x
Risky
Debt / Equity
0.58x
Moderate
Interest Coverage
-

Shareholder Signals

Capital returns and dilution checks sourced from statements and insider filings.

Buyback Yield
1.3%
Positive
Net Insider Buys
-13
Selling

Peer Comparison

TickerPrice
JNJJOHNSON & JOHNSON
$265.58
Company Profile

About the Company

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Next Earnings Date

Oct 13, 2026

Loading latest news...

Revenue segmentation

Loading segment disclosures…